NYSE - Delayed Quote USD

Penumbra, Inc. (PEN)

Compare
202.32 -0.08 (-0.04%)
At close: August 30 at 4:00 PM EDT
202.32 0.00 (0.00%)
After hours: August 30 at 5:05 PM EDT
Loading Chart for PEN
DELL
  • Previous Close 202.40
  • Open 202.35
  • Bid 196.05 x 800
  • Ask 202.58 x 800
  • Day's Range 199.86 - 203.84
  • 52 Week Range 148.00 - 302.00
  • Volume 267,470
  • Avg. Volume 457,861
  • Market Cap (intraday) 7.859B
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) 595.06
  • EPS (TTM) 0.34
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 198.57

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

www.penumbrainc.com

4,200

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PEN

View More

Research Reports: PEN

View More

Performance Overview: PEN

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PEN
19.57%
S&P 500
18.42%

1-Year Return

PEN
21.89%
S&P 500
25.59%

3-Year Return

PEN
25.57%
S&P 500
25.26%

5-Year Return

PEN
39.40%
S&P 500
93.14%

Compare To: PEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PEN

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    7.86B

  • Enterprise Value

    7.75B

  • Trailing P/E

    578.06

  • Forward P/E

    81.30

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.96

  • Price/Book (mrq)

    6.77

  • Enterprise Value/Revenue

    6.83

  • Enterprise Value/EBITDA

    408.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.26%

  • Return on Assets (ttm)

    3.32%

  • Return on Equity (ttm)

    1.28%

  • Revenue (ttm)

    1.13B

  • Net Income Avi to Common (ttm)

    14.23M

  • Diluted EPS (ttm)

    0.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    339.7M

  • Total Debt/Equity (mrq)

    19.71%

  • Levered Free Cash Flow (ttm)

    115.26M

Research Analysis: PEN

View More

Company Insights: PEN

People Also Watch